Device vs. Drug Trials: How Recruitment Strategy Differs

Not all clinical trials recruit the same way.

Device trials and drug trials may share similar goals — testing safety and effectiveness — but the way patients are identified, approached, and enrolled can be very different.

If recruitment strategy does not match the type of trial, delays are almost guaranteed.

Why Recruitment Strategy Cannot Be One-Size-Fits-All

It is easy to assume that recruitment is simply about finding eligible patients.

But the type of study changes everything.

Device trials often focus on procedures, interventions, or equipment use. Drug trials usually involve medication, dosing schedules, and longer monitoring periods.

Because of this, patient behaviour, site involvement, and eligibility can vary significantly.

Key Differences That Impact Recruitment

Understanding these differences early helps avoid common delays.

1. Patient Journey

Device trials are often linked to a procedure or treatment pathway.

Patients are usually already within a care setting, such as:

• Surgical pathways

• Specialist referrals

• Hospital-based treatments

Drug trials, on the other hand, may rely more on ongoing condition management. Patients might be:

• Managed in primary care

• Taking existing medication

• Open to switching or adding treatment

This affects how and where patients are identified.

2. Site Dependency

Device trials are more site-dependent.

They often require:

• Specific equipment

• Trained specialists

• Controlled environments

This limits the number of viable sites.

Drug trials are usually more flexible. They can be conducted across a wider range of locations, including GP practices and community settings.

3. Eligibility Complexity

Device trials often have stricter inclusion criteria tied to procedure suitability.

Drug trials may also be complex, but typically allow broader patient pools depending on the condition and treatment stage.

This difference directly impacts how many patients are available and how quickly they can be found.

Where Recruitment Often Breaks Down

Problems happen when the recruitment strategy does not match the study type.

For example:

• Treating a device trial like a broad outreach campaign

• Treating a drug trial as if all patients are already within specialist care

• Selecting sites without access to the right patient pathways

These mismatches slow everything down.

How to Fix Recruitment for Device Trials

Device trials need a more focused approach.

Success depends on being close to the patient journey.

A strong strategy should include:

• Identifying sites where procedures already happen

• Working closely with specialists and consultants

• Accessing patients at the point of care

Instead of casting a wide net, the goal is to target the right clinical settings.

TrialChoices supports this by connecting research teams with healthcare providers who already have access to relevant patient groups.

How to Fix Recruitment for Drug Trials

Drug trials benefit from scale and reach.

Patients may not always be in specialist care, so access through primary care becomes important.

A stronger approach includes:

1. Using GP networks

This helps identify patients earlier in their care journey.

2. Accessing real patient data

This improves feasibility and reduces guesswork.

3. Planning outreach early

This avoids delays once the study launches.

With the right access, drug trials can recruit faster without relying heavily on reactive marketing.

Why Early Planning Matters for Both

Whether it is a device or drug trial, one thing stays the same.

Recruitment must be planned early.

Waiting until the study starts to think about recruitment creates pressure and increases the risk of delays.

Early access to UK patient populations allows teams to:

• Validate feasibility

• Choose the right sites

• Align strategy with patient pathways

TrialChoices focuses on enabling this early visibility, helping studies start stronger.

The Role of Healthcare Pathways

Both trial types depend on healthcare systems.

The difference is how they use them.

Device trials rely heavily on secondary care and specialist settings. Drug trials often depend on primary care and broader patient access.

Understanding this helps shape the recruitment model.

Working through established healthcare pathways also improves trust and response rates, as patients are approached through familiar providers.

Why Speed Still Matters

Even with the right strategy, timing is critical.

Delays in recruitment can lead to:

• Extended timelines

• Higher costs

• Pressure on sites

But speed should not come at the expense of accuracy.

The goal is to identify suitable patients quickly, not just more patients.

TrialChoices supports both speed and precision by enabling practices to review their own patient data and match it to study criteria.

Signs Your Strategy Is Misaligned

Some signs are easy to spot:

• Slow enrolment despite strong outreach

• High screening failure rates

• Difficulty finding patients at selected sites

• Frequent changes to recruitment plans

These often point to a mismatch between trial type and recruitment approach.

A Better Way to Approach Recruitment

Recruitment works best when it reflects how patients move through the healthcare system.

That means:

• Aligning device trials with specialist care

• Aligning drug trials with broader patient access

• Using real data to guide decisions

• Planning early instead of reacting later

TrialChoices helps bring this together by connecting global research with UK healthcare providers and patient populations.

Final Thoughts

Device and drug trials may seem similar, but recruitment strategies for each are very different.

When those differences are ignored, delays follow.

When they are understood and planned for early, recruitment becomes more efficient and predictable.

With the right access to UK patients and better alignment with healthcare pathways, research teams can avoid common challenges and keep studies on track.

Contact TrialChoices

If you need help improving recruitment for device or drug trials, TrialChoices can support your strategy.

Call +44 (0) 07711 248 610  or email info@trialchoices.org to learn how to connect with UK patients faster and more effectively.